Emergent BioSolutionsEBS announced that a new phase I study has begun at the University of Oxford that will evaluate the use of its modified vaccinia Ankara (MVA) Ebola Zaire vaccine candidate as a prime boost to GlaxoSmithKline's GSK Chimp Adenovirus type 3 Ebola vaccine candidate.
The study will enroll 38 volunteers and be conducted in the UK and is being supported by a grant from the Wellcome Trust and the UK Department for International Development. Emergent BioSolutions manufactured the supply of MVA Ebola Zaire vaccine candidate to be used in this phase I study.
We remind investors that earlier this year, Emergent BioSolutions had entered into agreements with the University of Oxford, Glaxo and the National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIAID) for its MVA Ebola Zaire vaccine candidate.
Glaxo's Ebola vaccine candidate has shown encouraging immune responses and an acceptable safety and reactogenicity profile in ongoing phase I trials to date. Meanwhile, Emergent BioSolutions conducted a proof-of-concept work and manufactured the MVA Ebola vaccine candidate at a 200L scale in an avian cell line, which had previously been licensed to the company.
We are encouraged by the Ebola vaccine candidate's progress. We note that no treatment or vaccine is currently approved for Ebola. Several companies including Tekmira Pharmaceuticals TKMR are developing Ebola vaccines and treatments. We expect investor interest to remain on Ebola vaccine/treatment related updates. The companies working on Ebola therapies stand to make the most of it.
Emergent BioSolutions currently carries a Zacks Rank #3 (Hold). Gilead Sciences Inc. GILD is a better-ranked stock in the health care space carrying a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report